Charles Bavington, GlycoMar
What is your background and current job role?
I am the founder of GlycoMar and a biochemist with over 15 years experience in marine biotechnology. I graduated of the University of Edinburgh and then completed my PhD at the same university, studying proteoglycan metabolism in cartilage. This was followed by postdoctoral research at Dunstaffnage marine lab studying invertebrate glycans and cell adhesion. Subsequently I worked for Integrin Advanced Biosystems Ltd, a marine biotechnology and testing company, holding the positions of Operations Manager and Research & Development Manager. My commercial interests are in entrepeneurship and development of effective life science innovation business models. My scientific interest is in glycobiology and its role in cell-cell interactions.
What Industrial Biotechnology and Bioenergy (IBBE) related project is currently being undertaken by your organisation?
GlycoMar is a biotechnology company discovering and developing products for the healthcare and personal care markets. The company, founded in 2005, has an established discovery platform technology based on glycobiology products, which generates valuable intellectual property. The company evaluates the functional properties of its novel glycobiology products to identify the best candidates for development and the best market application, which include pharmaceutical, consumer healthcare, cosmetic and nutraceutical.
GlycoMar is developing novel consumer healthcare products addressing inflammatory disorders such as eczema and rhinitis, and pharmaceutical products that address unmet clinical needs in the treatment of inflammatory diseases such as psoriasis, asthma, and inflammatory bowel disease. The company is developing cosmetic ingredients for the skincare market and nutraceutical ingredients for the supplements and functional food markets. Our development programme is being carried out both in house and with commercial partners.
GlycoMar seeks to develop its discoveries to generate value through out licensing. The value of GlycoMar’s technology has been demonstrated through early stage Licensing and Collaboration deals.
We have developed and marketed a novel polysaccharide product from the marine microalga Prasinococcus capsulatus. The product is used in cosmetic products, healthcare products, and is being developed as a sugar replacement for use in confectionary. We continue to develop new polysaccharides for healthcare application. We are working on microalgae, cyanobacteria, and macroalgae products. Our covers all aspects of discovery and development of novel polysaccharides.
What do you think the challenges related to this project are in the next 1-5 years?
The biggest challenges we face are associated with product yield and production scale-up.
How can other CBMNet members help you and your organisation with your research?
Increase yield by manipulation of transport processes involved in growth of photosynthetic organisms and production of polysaccharide products.
You can contact Charles at Charlie@glycomar.com.